3,682 results match your criteria Neutrophilic Eccrine Hidradenitis

Contribution of mycobiota to the pathogenesis of spondyloarthritis.

Joint Bone Spine 2021 Jun 21:105245. Epub 2021 Jun 21.

Service de Rhumatologie, Hôtel-Dieu, CHU Nantes, Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.

This review lists current evidences for a contribution of gut mycobiota to the pathogenesis of SpA and related conditions. Gut mycobiota has a small size as compared to bacterial microbiota, but an even greater inter and intra-individual variability. Although most fungi (brought by food or air) are only transitory present, a core mycobiota of gut resident fungi exists, and interplays with bacteria in a complex manner. Read More

View Article and Full-Text PDF

Surgical reconstruction of massive scrotal lymphedema associated with hidradenitis suppurativa: a case report.

Gland Surg 2021 May;10(5):1800-1805

Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, Shanghai Jiao Tong University, Shanghai, China.

Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory cutaneous disease affecting apocrine glands. It can be associated with lymphedema of the surrounding tissues and most commonly affects scrotum. As a debilitating complication of HS, lymphedema can cause significant morbidity and further exacerbate HS condition, thus causing a vicious cycle. Read More

View Article and Full-Text PDF

Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa, real-life data.

Ital J Dermatol Venerol 2021 Jun 23. Epub 2021 Jun 23.

Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Background: Hidradenitis suppurativa (HS) is characterized by periodic worsening of both clinical manifestations and symptoms. The aim was to investigate the role of flare outbreak as a possible predictive factor of response to Adalimumab.

Methods: 115 HS patients in treatment with adalimumab, with moderate-severe HS, ≥3 abscesses and inflammatory-nodules (ANs) from 5 Italian centers were included in this retrospective analysis. Read More

View Article and Full-Text PDF

Ultrasound-guided photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in hidradenitis suppurativa: a retrospective study of 41 patients.

Photodermatol Photoimmunol Photomed 2021 Jun 22. Epub 2021 Jun 22.

Department of Dermatology, Hospital Miguel Servet, Zaragoza, Spain.

Background: Photodynamic therapy for hidradenitis suppurativa (HS) is a therapeutic alternative with a good safety profile, but its effectiveness has yet to be demonstrated.

Objectives: To demonstrate the effectiveness of PDT with intralesional methylene blue in HS lesions.

Methods: A retrospective cross-sectional study was performed. Read More

View Article and Full-Text PDF

Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.

Arch Dermatol Res 2021 Jun 22. Epub 2021 Jun 22.

Department of Dermatology, Stony Brook University Hospital, Stony Brook, NY, USA.

Ustekinumab is approved for the treatment of psoriasis and Crohn's disease. Because many dermatological conditions are due to immune-mediated development, ustekinumab may be effective in other conditions. A systematic review of the off-label uses of ustekinumab, as well as on-label adverse effect, was performed, reporting on clinical improvement. Read More

View Article and Full-Text PDF

Hidradenitis Suppurativa Among Patients with Human Immunodeficiency Virus: Investigating Patient and Disease Characteristics, and Misdiagnosis.

Br J Dermatol 2021 Jun 22. Epub 2021 Jun 22.

University of North Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A.

Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory disease prevalent in 0.1% to 2% of the general population. Previous literature has linked human immunodeficiency virus (HIV) to increased rates and severity of chronic inflammatory disorders such as psoriasis and psoriatic arthritis, leading us to explore whether associations between HIV and HS may exist. Read More

View Article and Full-Text PDF

Outcomes of Pregnancy and Childbirth in Women with Hidradenitis Suppurativa.

J Am Acad Dermatol 2021 Jun 18. Epub 2021 Jun 18.

Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address:

Background: Many women affected by hidradenitis suppurativa (HS) are of childbearing age. To date, the literature is limited on pregnancy-related outcomes for women with HS.

Objective: To investigate maternal and obstetric outcomes, and treatment utilization among women with HS. Read More

View Article and Full-Text PDF

A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab.

Int J Dermatol 2021 Jun 20. Epub 2021 Jun 20.

Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

View Article and Full-Text PDF

Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies.

Front Oncol 2021 3;11:687432. Epub 2021 Jun 3.

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.

Cancer is one of the several comorbidities that have been linked with chronic cutaneous inflammatory diseases namely psoriasis/psoriatic arthritis and hidradenitis suppurativa. Although the chronic inflammatory state, typical of the diseases, may induce pro-tumorigenic effects, the debate whether or not the drugs currently used in clinical practice do in facts increase a patient's risk of malignancy remains largely unsolved. The therapeutic armamentarium has been greatly enhanced at least in the last two decades with the advent of biologics, a heterogeneous group of laboratory-engineered agents with more in the pipeline, and other targeted small molecules. Read More

View Article and Full-Text PDF

Prevalence of Depression among Children, Adolescents, and Adults with Hidradenitis Suppurativa.

J Am Acad Dermatol 2021 Jun 15. Epub 2021 Jun 15.

Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra / Northwell, Hempstead, NY, USA. Electronic address:

Background: Information on prevalence of depression among children, adolescents and adults with hidradenitis suppurativa (HS) is limited.

Objective: To compare prevalence of depression in HS patients with that of controls.

Methods: Cross-sectional analysis of 38,140 adult and 1,162 pediatric HS patients and controls identified using electronic health records data. Read More

View Article and Full-Text PDF

Hidradenitis suppurativa-specific, patient-reported outcome measures.

J Eur Acad Dermatol Venereol 2021 Jul;35(7):1420-1421

Department of Dermatology and Venereology, National Medical University, Kiev, Ukraine.

View Article and Full-Text PDF

Hidradenitis Suppurativa From a Patient Perspective Including Symptoms and Self-Treatment.

J Cutan Med Surg 2021 Jun 17:12034754211024157. Epub 2021 Jun 17.

12365 Division of Dermatology, Department of Medicine, University of Ottawa and The Ottawa Hospital, Canada.

Introduction: Hidradenitis Suppurativa (HS) is a chronic inflammatory disordercommonly affecting body folds. It can significantly impair quality of life due to the physical, psychological, and socialturmoil experienced by patients. Treatment remains a challenge. Read More

View Article and Full-Text PDF

Long-Term Follow-Up after Radiotherapy of Hidradenitis Suppurativa.

Jurr Boer

Dermatology 2021 Jun 16:1-7. Epub 2021 Jun 16.

Department of Dermatology, Deventer Hospital, Deventer, The Netherlands.

Background: Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT. Read More

View Article and Full-Text PDF

Vulval squamous cell carcinoma arising from hidradenitis suppurrativa.

BMJ Case Rep 2021 Jun 15;14(6). Epub 2021 Jun 15.

Pathology North, New Lambton Heights, New South Wales, Australia.

A 47- year-old woman developed a rapidly enlarging vulvar mass. Although the clinical appearance suggested malignancy, its lack of atypia and invasion on initial superficial biopsy delayed the pathological diagnosis. It was not until a large incisional biopsy was performed that showed the diagnosis of verrucous squamous cell carcinoma (VSCC) involving pre-existing sinuses of hidradenitis suppurativa (HS). Read More

View Article and Full-Text PDF

Global data analysis supports smoking as the fundamental element associated with geographic gender disparities in hidradenitis suppurativa.

Br J Dermatol 2021 Jun 15. Epub 2021 Jun 15.

Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Hidradenitis suppurativa (HS), or acne inversa, is a painful and recurrent inflammatory cutaneous disorder involving the terminal hair follicles of intertriginous and gluteal areas. Epidemiological studies have revealed geographic differences regarding the demographic and clinical characteristics of HS. The gender distribution of HS patients is diverse among different countries. Read More

View Article and Full-Text PDF

Adverse Pregnancy and Maternal Outcomes in Women with Hidradenitis Suppurativa.

J Am Acad Dermatol 2021 Jun 11. Epub 2021 Jun 11.

Department of Dermatology, Donald & Barbara Zucker School of Medicine at Hofstra Northwell, Hempstead, NY. Electronic address:

Background: Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age. However, pregnancy and maternal outcomes for women with HS are unknown.

Objective: To compare risk of adverse pregnancy and maternal outcomes among women with and without HS, and to evaluate influence of comorbid conditions. Read More

View Article and Full-Text PDF

Should We Scan Hidradenitis Suppurativa Patients? A Systematic Review of Radiologic Findings.

Adv Skin Wound Care 2021 Jul;34(7):1-10

At the Universidade Federal do Rio de Janeiro, Brazil, Gabriel Gutfilen-Schlesinger, MSc, is PhD Student, Postgraduate Program of Medicine; Sergio Augusto Lopes de Souza, PhD, is Associate Professor, Department of Radiology; and Bianca Gutfilen, PhD, is Full Professor, Department of Radiology. Acknowledgments: The authors thank José Marcos Telles da Cunha, MD, PhD, for his thoughtful insights during various stages of manuscript preparation. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (Finance Code 001) and the Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro. The authors have disclosed no other financial relationships related to this article. Submitted October 23, 2020; accepted in revised form January 7, 2021.

Objective: To bring awareness and close gaps between dermatologists and radiologists about the contribution of imaging techniques for diagnosis, treatment, and follow-up of hidradenitis suppurativa (HS).

Data Sources: Investigators searched the PubMed database for articles on HS and radiology techniques.

Study Selection: Databases were searched up to December 2018. Read More

View Article and Full-Text PDF

[Impact of LAight therapy on hidradenitis suppurativa care].

Hautarzt 2021 Jun 14. Epub 2021 Jun 14.

Klinik für Dermatologie und Venerologie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease with high burden for patients and limited treatment options. We recently analyzed the efficacy of local treatment with LAight therapy, a combination of intense pulsed light (IPL) and radiofrequency (RF).

Objectives: The aim of the present survey was to compare care of HS patients under LAight with standard care prior to therapy. Read More

View Article and Full-Text PDF

Biologic survival in hidradenitis suppurativa: much done, more to do.

R Hambly B Kirby

Br J Dermatol 2021 Jun 14. Epub 2021 Jun 14.

The Charles Centre, Department of Dermatology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.

View Article and Full-Text PDF

Autoinflammatory keratinitzation diseases (AIKDs.

Actas Dermosifiliogr 2021 Jun 9. Epub 2021 Jun 9.

Servicio de Dermatología, Consorci Corporació Sanitària Parc Taulí, Universidad Autónoma de Barcelona, Spain.

Autoinflammatory keratinization disease (AiKD) is a novel clinical concept encompassing diseases with a genetic background and mixed pathogenic mechanisms of autoinflammation and autoimmunity, leading to an aberrant keratinization of the skin. Recent advances in medical genetics have revealed genetic causes and/or predisposing factors for a number of AiKD's, such as mutations in IL36RN related with pustular psoriasis, acrodermatitis continua and hidradenitis suppurativa, in CARD14 in pityriasis rubra pilaris type V and some forms of pustular psoriasis, and in NLRP1 related with familial keratosis lichenoides chronica (KLC). It is suspected that AiKD pathophysiology would also be involved in non-monogenic disorders. Read More

View Article and Full-Text PDF

TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines.

AIDS 2021 Jun 10. Epub 2021 Jun 10.

Department of Medicine, University of California, San Francisco, CA, USA Division of Hospital Medicine, University of California, San Francisco, CA, USA Department of Pathology, University of California, San Francisco, CA, USA Division of Gastroenterology, University of California, San Francisco, CA, USA Division of Infectious Diseases, University of California, San Francisco, CA, USA Division of Experimental Medicine, University of California, San Francisco, CA, USA Division of HIV, Infectious Diseases, and Global Medicine University of California, San Francisco, CA, USA.

Background: Despite the risks of immunosuppression, recommendations regarding screening for HIV infection prior to initiation of biologic therapies targeting common rheumatologic disorders, including inflammatory bowel disease (IBD) and inflammatory arthritides, are limited. Few cases of patients started on biologics while living with undiagnosed HIV infection have been reported.

Methods: We report 3 cases of patients initiated on biologics in the absence of recent or concurrent HIV screening who developed refractory disease or unanticipated complications and were later found to have undiagnosed chronic HIV infection. Read More

View Article and Full-Text PDF

[CME Dermatology 23/Answers: Hidradenitis suppurativa].

Praxis (Bern 1994) 2021 Jun;110(8):471-472

Institut für Dermatologie und Venerologie, Stadtspital Waid und Triemli, Zürich.

CME Dermatology 23/Answers: Hidradenitis suppurativa Hidradenitis suppurativa (Acne inversa) is a chronic skin disease characterized by recurrent inflammatory nodules, abscesses, and scarring mainly in the intertriginous areas. The prevalence is estimated to be 0.05 to 4. Read More

View Article and Full-Text PDF

Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous Tumor Necrosis Factor-Alpha Treatment Failure.

J Invest Dermatol 2021 Jun 4. Epub 2021 Jun 4.

University of North Carolina School of Medicine, Department of Dermatology, Chapel Hill, NC, USA. Electronic address:

View Article and Full-Text PDF

Squamous Cell Carcinoma in Hidradenitis Suppurativa Lesions Following Tumor Necrosis Factor α Inhibitors.

Cutis 2021 Apr;107(4):E5-E7

Dr. Cooper is from the Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. Drs. Cowdrey, Linos, and Lefferts are from the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. Dr. Cowdrey is from the Section of Dermatology, and Drs. Linos and Lefferts are from the Department of Pathology and Laboratory Medicine, Dermatopathology Division. Dr. Basic is from the James A. Haley Veterans Hospital, Tampa, and the Department of Dermatology, Morsani College of Medicine, University of South Florida, Tampa.

View Article and Full-Text PDF

A case of hidradenitis suppurativa with perifolliculitis capitis abscedens et suffodiens successfully treated with a human anti- tumor necrosis factor monoclonal antibody.

Clin Exp Dermatol 2021 Jun 7. Epub 2021 Jun 7.

Department of Dermatology, Hirosaki University Graduate School of Medicine, Aomori, Japan.

Hidradenitis suppurativa (HS) is a chronic autoinflammatory skin disorder characterized by recurrent painful nodules, abscesses, sinus tracts, and scarring on intertriginous body areas. Perifolliculitis capitis abscedens et suffodiens (PCAS) is a component of the follicular occlusion tetrad along with HS, acne conglobata, and pilonidal cyst. We report a case of HS with PCAS that was successfully treated with adalimumab, a human anti-tumor necrosis factor (TNF) monoclonal antibody. Read More

View Article and Full-Text PDF

Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa.

Cureus 2021 Apr 30;13(4):e14769. Epub 2021 Apr 30.

Hematology and Medical Oncology, Jamaica Hospital Medical Center, Queens, USA.

Adalimumab-induced thrombocytopenia is a rarely occurring condition that may present with hemorrhagic manifestations. This report describes a case of a patient who presented with severe, symptomatic thrombocytopenia while on adalimumab for the treatment of hidradenitis suppurativa. The patient responded to treatment with steroids, intravenous immunoglobulin (IVIG), and platelet transfusion, in addition to discontinuation of adalimumab. Read More

View Article and Full-Text PDF

Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials.

Medicine (Baltimore) 2021 Jun;100(22):e26190

Department of Medical Education, Hualien Tzu Chi Hospital, Hualien.

Background: Adalimumab is used as a first-line biologic agent in the management of moderate-to-severe hidradenitis suppurativa (HS). The objective of the present study was to evaluate the efficacy and safety of adalimumab in patients with moderate-to-severe HS.

Methods: We performed a systematic review and meta-analysis according to Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. Read More

View Article and Full-Text PDF